Phaseline

Targets › NGF

NGF (Beta-nerve growth factor): drug programs, companies and trials

3 programs from 3 companies in 3 trials: 2 Phase 1, 1 Phase 4; Oncology, Ophthalmology, Neurology; next expected readout Dec 2026.

Nerve growth factor is important for the development and maintenance of the sympathetic and sensory nervous systems. Extracellular ligand for the NTRK1 and NGFR receptors, activates cellular signaling cascades to regulate neuronal proliferation, differentiation and survival (Probable). (UniProt, P01138)

Open in Phaseline: the race on NGF, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
The Third Affiliated hospital of Zhejiang Chinese Medical UniversityNerve growth factor (NGF)
Neurotrophic factor to promote nerve regeneration and functional recovery
NGFPhase 4Ischemic StrokeDec 2027
Krystal BiotechKB801
Replication-defective, non-integrating HSV-1 vector delivering human nerve growth factor (
NGFPhase 1Neurotrophic KeratitisDec 2026
Shenyang Sunshine PharmaceuticalSSS40
Humanized nerve growth factor (NGF) antibody
NGFPhase 1Cancer Pain–

Conditions

Cancer Pain (1) Neurotrophic Keratitis (1) Ischemic Stroke (1)

Modalities

antibody (1), protein or peptide (1), small molecule (1)

Companies

Shenyang Sunshine Pharmaceutical (1) Krystal Biotech (1) The Third Affiliated hospital of Zhejiang Chinese Medical University (1)

Related targets

–

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.